Abstract: This disclosure relates generally to VMAT2 inhibitor compounds of Formula (Ia): and pharmaceutically acceptable salts thereof, as well as compositions and methods related thereto.

Abstract: A flow-cytometer has an excitation light source generating an excitation light that excites one or more bio-cells in a bio-sample carried by a flow path to luminesce. The flow-cytometer includes a spectrum dispersive element that disperses the luminescent light generated by the bio-sample into a photo-detector array. The flow-cytometer further includes a digital signal processor (DSP) that receives signals from the photo-detector array and generates a self-triggering signal based on the luminescent light generated by the bio-cells in bio-sample. The self-triggering signal triggers data capture in the DSP to improve synchronization with the data generated from signals received from the photo-detector array.

Abstract: The invention relates to compositions and methods containing hemp and/or Cannabis-derived cannabidiol (CBD) for topical use in treating female sexual dysfunction induced by antidepressants, including, e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin/norepinephrine reuptake inhibitors (SNRIs), and other anti-depressants.

Abstract: Described herein is an implantable medical device that includes a body having one or more ultrasonic transducers configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy, two or more electrodes in electrical communication with the ultrasonic transducer, and a clip attached to the body that is configured to at least partially surround a nerve and/or a filamentous tissue and position the two or more electrodes in electrical communication with the nerve. In certain examples, the implantable medical device includes two ultrasonic transducers with orthogonal polarization axes. Also described herein are methods for treating incontinence in a subject by converting energy from ultrasonic waves into an electrical energy that powers a full implanted medical device, and electrically stimulating a tibial nerve, a pudendal nerve, or a sacral nerve, or a branch thereof, using the fully implanted medical device.

Abstract: This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.

Abstract: A microfluidic chip can include a microfluidic network that comprises a port, one or more test volumes, and one or more channels through which fluid must flow from the port to the test volume(s). A crosslinkable material can also be disposed within the microfluidic network such that the crosslinkable material is flowable through the channel(s). The crosslinkable material of the microfluidic chip may be exposed to light and/or heat to crosslink the material within and thereby occlude the channel(s).

Abstract: Abstract: Provided herein are compositions comprising EV, e.g., exosome, which comprises STING agonists and methods of using such compositions for the treatment of neuroimmunological disorders. Methods of producing the compositions (e.g., EVs comprising a STING agonist) described herein are also provided.

Abstract: Methods and systems are provided for microscope auto-focusing. In one example, a a method for microscope auto-focusing comprises: acquiring a plurality of contrast samples of an imaged subject; modeling a contrast distribution based on the plurality of contrast samples; acquiring an additional contrast sample based on the contrast distribution; modeling a corrected contrast distribution based on the additional contrast sample and the plurality of contrast samples; and focusing the imaged subject based on the corrected contrast distribution.

Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Abstract: Fusion constructs encoding RNase-H-like domain containing compositions are disclosed. Disclosed are also compositions and methods utilizing RNase-H-like domain containing compositions for the treatment of cancer. Also disclosed are the methods of making and using the RNase-H-like domain containing compositions in treating various diseases, conditions, and cancer.

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Abstract: The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

Abstract: A method of treating cardiovascular disease in a patient includes generating, by an implantable stimulator configured to be implanted beneath a skin surface of the patient, stimulation sessions at a duty cycle that is less than 0.05 and applying, by the implantable stimulator in accordance with the duty cycle, the stimulation sessions to a location, within the patient, that is associated with the cardiovascular disease. The duty cycle is a ratio of T3 to T4. Each stimulation session included in the stimulation sessions has a duration of T3 minutes and occurs at a rate of once every T4 minutes.

Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.

Abstract: Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.

Abstract: The methods, procedures, kits, and devices described herein assist with the healing process of tissue that was previously or simultaneously treated for a therapeutic or cosmetic effect. The methods, procedures, kits, and devices described herein can also provide temporary simulated results of a cosmetic procedure to allow for visual assessment to select the type of procedure or for treatment planning in advance of the surgical procedure.

Abstract: The present disclosure relates extracellular vesicles, e.g., exosomes, comprising an antigen-binding moeity, e.g., a single-domain antigen-binding moeity, e.g., a vNAR, a VHH, or a fragment thereof, that specifically binds transferrin receptor, and methods of making and using the same.

Abstract: An improved agent and treatment method for a broad variety of diseases in both animals and humans is disclosed. The agent is an inventive composition comprising a bacterial-based culture. Particularly, the inventive composition disclosed herein is an active molecule produced by a Gram-negative bacterial strain that is a member of the genus Brevundimonas. Consumption of the inventive composition by way of liquid or dry feed produces a broad range of health benefits and has proven effective in the prevention and treatment of disease. The bacterium of the disclosed composition selectively modulates Toll-like receptors (TLRs) for the prevention and treatment of disease such as coccidiosis. Specific actions include but are not limited to improvement of gut health, acceleration or enhancement of immune response using a natural immune modulator, and the promotion of animal growth.

Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.

Abstract: A method is provided for treating a recipient with a biological product obtained from at least one donor that may be the same as, or different from, the recipient. The method includes identifying a targeted level of gene expression of a first gene in a biological product to be transferred from at least one donor to a recipient; treating the at least one donor to achieve the targeted level of gene expression of the first gene in the biological product; and transferring the biological product from the at least one donor to the recipient.